Orexigen Therapeutics, Inc. (OREX) news stock charts
Orexigen Therapeutics, Inc. (OREX) Investment Summary:
Orexigentm Therapeutics, Inc. (“Orexigen”, “we”, “our” and “us”) is a biopharmaceutical company focused on the development of pharmaceutical product candidates for the treatment of central nervous system, or CNS, disorders, including obesity. Our lead product candidates targeted for obesity are Contravetm, which is in Phase III clinical trials, and Empatictm, which is in the later stages of Phase II clinical development. Each of these product candidates is a combination of generic drugs, which we have systematically screened for synergistic CNS activity. We seek to combine chemical entities that, individually, have already received regulatory approval and have been commercialized previously, into new product candidates that we believe address unmet medical needs and are patentable. We are testing these combinations in an effort to demonstrate adequate efficacy and safety for potential regulatory approval. ... More..."http://secfilings.nasdaq.com/edgar_conv_html%2f2008%2f03%2f27%2f0000936392-08-000233.html#FIS_BUSINESS"OREXIGEN THERAPEUTICS INC (OREX:NASDAQ)
Snapshot of OREXIGEN THERAPEUTICS INC (OREX)
|
OPEN
$6.12
|
PREVIOUS CLOSE
$6.06
|
|
|
DAY HIGH
$6.24
|
DAY LOW
$5.89
|
|
|
52 WEEK HIGH
09/21/09 - $10.83
|
52 WEEK LOW
04/29/09 - $1.78
|
|
|
MARKET CAP
286.6M
|
AVERAGE VOLUME 10 D
499.2K
|
|
|
EPS TTM
$-1.72
|
SHARES OUTSTANDING
47.2M
|
|
|
OREX Does Not Pay Dividends
|
P/E TTM
--
|
|
| K = Thousands M = Millions B = Billions | ||
Key developments for OREXIGEN THERAPEUTICS INC (OREX)
OrexigenR Therapeutics, Inc. and Patheon Inc. announced a long-term agreement for commercial manufacturing of ContraveR (naltrexone HCL sustained release (SR)/bupropion HCL SR) as well as development of future formulations of Orexigen products. The financial terms of the deal were not disclosed.
Orexigen Therapeutics, Inc. reported unaudited earnings results for the fourth quarter and year ended December 31, 2009. For the quarter, the company reported a net loss of $15.0 million, or $0.32 loss per diluted share attributable to common stockholders, as compared to a net loss of $22.1 million, or $0.64 loss per diluted share attributable to common stockholders, for the same period in 2008. Total revenues were $22,000 against $22,000 for the same period in 2008. Loss from operations was $14.8 million against $22.1 million for the same period in 2008. For the year ended December 31, 2009, the company reported a net loss of $66.6 million, or $1.67 loss per diluted share attributable to common stockholders, as compared to a net loss of $93.2 million, or $2.76 loss per diluted share attributable to common stockholders, for 2008. Total revenues were $88,000 against $88,000 for the same period in 2008. Loss from operations was $65.5 million against $94.8 million for the same period in 2008.
Orexigen Therapeutics, Inc. announced that they will report Q4, 2009 results on 03/09/2010
Orexigen Therapeutics, Inc. financial resources
OREX Competitors
| Company | Last | Change |
| Inhibitex Inc | $1.30 USD | -0.06 |
| MAP Pharmaceuticals Inc | $16.05 USD | +0.03 |
| NeurogesX Inc | $8.40 USD | +0.08 |
| Targacept Inc | $19.23 USD | +0.54 |
| Vanda Pharmaceuticals Inc | $11.76 USD | -0.06 |
| Market data is delayed at least 15 minutes. | ||
Industry Analysis
| Valuation | OREX | Industry Range |
| Price/Earnings | NM | Not Meaningful |
| Price/Sales | 3,248.0x |
|
| Price/Book | 3.8x |
|
| Price/Cash Flow | NM | Not Meaningful |
| TEV/Sales | 2,109.5x |
|
|
OREX |
||
OREX transactions
| Type Date |
Target | |
| No transactions in the last 6 months. | ||
More Recent Financial News About Orexigen Therapeutics, Inc.
Orexigen(R) Therapeutics to Speak at Barclays Capital 2010 Global Healthcare Conference
Read article
Orexigen(R) Therapeutics and Patheon Announce Exclusive Manufacturing Agreement for Contrave(R)
Read article
Orexigen signs Patheon to manufacture weight drugs
Read article
OREXIGEN THERAPEUTICS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement
Read article
Orexigen Therapeutics, Inc. Earnings Call scheduled for 8:00 am ET today
Read article
Orexigen(R) Therapeutics Appoints Peter Honig, M.D. to Board of Directors
Read article
Orexigen(R) Therapeutics Announces Fourth Quarter and Year Ended December 31, 2009 Financial Results
Read article
Orexigen(R) Therapeutics Schedules March 9, 2010 Webcast Discussion of Financial Results for the Fourth Quarter and Year Ended December 31, 2009
Read article
Orexigen(R) Therapeutics Announces Fourth Quarter and Year Ended December 31, 2009 Financial Results
Read article
OREXIGEN THERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements a
Read article
Orexigen(R) Therapeutics Schedules March 9, 2010 Webcast Discussion of Financial Results for the Fourth Quarter and Year Ended December 31, 2009
Read article
Orexigen(R) Therapeutics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
Read article
OREXIGEN THERAPEUTICS, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Other Events, Financial St
Read article
Orexigen(R) Therapeutics Appoints Peter Honig, M.D. to Board of Directors
Read article
Orexigen(R) Therapeutics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
Read article